Phio Pharmaceuticals (PHIO) Tax Rate (2017 - 2025)
Phio Pharmaceuticals' (PHIO) quarterly Tax Rate came in at 105.83% in Q4 2025, down 8518.0% on a YoY basis from 1.26% in Q4 2024, and down 412.52% quarter-over-quarter from 20.65% in Q4 2024.
Powered by 
Analysis
Phio Pharmaceuticals (PHIO) Tax Rate (2017 - 2025) Analysis & Trends
Phio Pharmaceuticals (PHIO) has reported Tax Rate for 3 consecutive years, with 105.83% the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Tax Rate fell 8518.0% year-over-year to 105.83%; the trailing twelve-month figure through Dec 2025 stood at 30.21% (down 2555.0% YoY), and the FY2025 full-year result was 29.7%, down 2499.0% from the prior year.
- Tax Rate retreated to 105.83% in Q4 2025 per PHIO's latest filing, from 20.65% in the prior quarter.
- Across five years, Tax Rate topped out at 20.65% in Q4 2024 and bottomed at 105.83% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Tax Rate (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 14.20% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -2.36% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 20.98% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 15.11% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -10.89% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -1.96% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 7.49% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 26.36% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 1.34% |
| 10 | Phio Pharmaceuticals | 12.08 Mn | 12.08 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -105.83% |
| Dec 31, 2024 | -20.65% |
| Mar 31, 2017 | 22.89% |